Niraparib CAS NO 1038915-60-4
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
Niraparib is used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Send your message to us
(* We will reply your inquiry to this Email as soon as we see it.)
